Navigation Links
Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
Date:10/29/2010

dequate response in MDD - Today Shire announced positive results from a Phase 2 clinical trial of VYVANSE as adjunctive therapy for patients who have had an inadequate response in their treatment of MDD. Given the encouraging results and the promise to treat a large unmet medical need, Shire will initiate Phase 3 trials of VYVANSE in patients with MDD mid 2011, following health authority meetings to establish the development program parameters. Phase 2 clinical trials in additional non-ADHD indications (treatment of negative symptoms and cognitive impairment in schizophrenia and for the treatment of cognitive impairment in depression) remain ongoing. SPD535 for the treatment of arteriovenous grafts in hemodialysis patients - SPD535 is a novel platelet reducing agent. Phase 1 development was initiated in the third quarter of 2009 and is ongoing. Data from Phase 1 clinical trials demonstrating positive proof-of-principle have been completed. The initial Phase 2 proof-of-concept program will target prevention of thrombotic complications associated with arteriovenous grafts in hemodialysis patients. Additional Phase 2 proof-of-concept clinical trials will also be initiated to assess opportunities in other indications. INTUNIV for ADHD in the EU - A clinical program to support the filing of a Marketing Authorization Approval for INTUNIV for the treatment of ADHD in children aged 6 to 17 in the EU has been initiated. Shire anticipates submission of the regulatory filing for INTUNIV in Europe will occur in 2013. OTHER THIRD QUARTER AND RECENT DEVELOPMENTS Acquisition of Movetis - On September 6, 2010 Shire launched a voluntary public takeover offer for all the shares in Movetis, a Belgium-based speciality GI company, for a fully diluted equity purchase price of EUR428 million (or EUR19 per share) in cash, equivalent to $592 million at closing of the transaction. - On October 12, 2010 the Company's wholly owned subsidiary, Shire Holdings Luxembourg S.a.r.l. acquired 99.21%
'/>"/>
SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
2. Reportlinker Adds Shire plc: PharmaVitae Profile
3. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
4. Shire plc - Statement re ProAmatine
5. Shire Proposes to Expand Specialist Gastrointestinal Portfolio
6. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
7. Shire Receives CHMP Positive Opinion for VPRIV(TM) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union
8. Shire plc Appoints Two New Board Directors
9. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
10. Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection)
11. INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... 2014 The Collaborative R&D Terms ... provides comprehensive understanding and unprecedented access to the ... the worlds leading life science companies. , The ... how and why companies enter collaborative R&D deals. ... negotiated deals terms provides critical insight into the ...
(Date:8/31/2014)... 01, 2014 Available spectra is ... for research and cultivation of a wide range ... proprietary LEDs with proven patented and pending wide ... light uniformity in critical applications in contrast to ... , “Our customers have a large variety of ...
(Date:8/31/2014)... August 31, 2014 This is ... state of the Epoxy Hardener industry in ... overview of the industry, including definitions, applications and ... domestic market analysis are provided with a focus ... the market. A comparison between the international and ...
(Date:8/29/2014)...  Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage ... and difficult to manufacture proteins including biosimilar therapeutics, ... results for the second quarter ended June 30, ... our initial public offering, we have the capital ... derived from our proprietary protein expression platform," stated ...
Breaking Biology Technology:Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 4Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 2Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8
... MELVILLE, N.Y., July 31 Gentiva Health,Services, ... provider of,comprehensive home health services, today reported strong ... revenues and admissions,in the Company,s Home Health segment., ... for the quarter ended June 29, 2008 included:, ...
... MD (creator of the Hydro-Pulse sinus irrigation device) describes ... anti-inflammatories directly into the sinus cavities using a pulsating ... his patients who experience symptoms of sinus infections, snoring ... ...
... Nektar,Therapeutics (Nasdaq: NKTR ) will announce its financial ... Wednesday, August 6, 2008, after the,close of U.S.-based financial ... a conference call to review the results,beginning at 5:00 ... The press release and a live audio-only Webcast of ...
Cached Biology Technology:Gentiva Reports Strong Second Quarter led by Home Health Segment 2Gentiva Reports Strong Second Quarter led by Home Health Segment 3Gentiva Reports Strong Second Quarter led by Home Health Segment 4Gentiva Reports Strong Second Quarter led by Home Health Segment 5Gentiva Reports Strong Second Quarter led by Home Health Segment 6Gentiva Reports Strong Second Quarter led by Home Health Segment 7Gentiva Reports Strong Second Quarter led by Home Health Segment 8Gentiva Reports Strong Second Quarter led by Home Health Segment 9Gentiva Reports Strong Second Quarter led by Home Health Segment 10Gentiva Reports Strong Second Quarter led by Home Health Segment 11Gentiva Reports Strong Second Quarter led by Home Health Segment 12Prominent Physician Achieves Success Using Topical Sinus Medications via Pulsitile Irrigation 2Nektar to Announce Financial Results for the Second Quarter of 2008 on Wednesday, August 6, 2008, After Close of U.S.-Based Financial Markets 2
(Date:8/29/2014)... A leading U.S. Ebola researcher from the University of Texas ... a blend of three monoclonal antibodies can completely protect monkeys ... days after infection, at a time when the disease is ... written an editorial for Nature discussing advances in ... Marburg virus are among the most deadly of pathogens, with ...
(Date:8/29/2014)... in German . ... is considered the oldest form of communication. Acting as ... example, the sexual attraction between males and females. Fish ... coordinate reproductive behavior in males and females. Scientists at ... Algarve in Faro, Portugal, and at the Max Planck ...
(Date:8/29/2014)... Tibetan plateau -- the largest topographic anomaly above sea ... profound effect on climate and its reflection of continental ... , Katharine Huntington and colleagues employ a cutting-edge geochemical ... fossil snail shells to investigate the uplift history of ... range widely on the timing of surface uplift of ...
Breaking Biology News(10 mins):Leading Ebola researcher at UTMB says there's an effective treatment for Ebola 2Ready for mating at the right time 2Ready for mating at the right time 3Snails tell of the rise and fall of the Tibetan Plateau 2Snails tell of the rise and fall of the Tibetan Plateau 3Snails tell of the rise and fall of the Tibetan Plateau 4Snails tell of the rise and fall of the Tibetan Plateau 5Snails tell of the rise and fall of the Tibetan Plateau 6Snails tell of the rise and fall of the Tibetan Plateau 7
... with Staphylococcus aureus bacteria, a leading cause of ... infections, including the antibiotic-resistant strain MRSA. University of ... the immense success of S. aureus the ability to ... to destroy white blood cells. The study was published Nov ...
... are more fattening than others? What about the risks ... for Nutrition (ASN) on December 5-7 for answers to ... in Clinical Nutrition Conference. The 3-day program ... several different satellite sessions, and networking opportunities. Credentialed media, ...
... Nov. 19, 2013   The Bensalem Township Police Department , ... in the field of DNA testing.  This pilot program known ... first of its kind in the country for law enforcement. ... local DNA database with over 6,000 DNA profiles consisting of ...
Cached Biology News:Staphylococcus aureus bacteria turns immune system against itself 2Advances and Controversies in Clinical Nutrition: Diet, Technology and Practice 290 Minute DNA Results, A First Of Its Kind, Coming To Bensalem 2
Gridded Cell Culture Petri Dish (20 mm molded in base), tissue-culture treated...
...
BD Biocoat Matrigel Matrix Thin Layer 35 mm Culture Dishes...
... Novagen's frozen Sf9 Insect Cells are derived from ... pretested for optimal growth, use in transfections, plaque ... are frozen in a protocol that optimizes recovery ... for growth in serum-free BacVector Insect Cell Medium ...
Biology Products: